Denver—For the minority of patients who develop significant immune-related adverse events (AEs) while taking checkpoint inhibitors, it is appropriate to intervene quickly by delaying treatment, adding corticosteroids or both.
Giving steroids does not affect the clinical outcomes from what we know so far, [and] it is really important that we play a role in stopping the inflammatory cascade early,” said Christopher Campen, PharmD, a clinical pharmacist at Greenville Health System